圣淘沙名胜世界

Be the most trusted biotech company

2025-07-25

From China’s First to Industry Benchmark | Five Years Since HANQUYOU's Global Approval, Benefiting over 260,000 Patients Worldwide
2025-07-14

Henlius’ HLX22 International Multicentre Phase 3 Head-to-Head Trial Administers First Dose to US Patient in HER2+ GC
2025-07-09

Henlius Receives Global Regulatory Approvals for Phase 2 MRCT of Its PD-L1 ADC HLX43 on NSCLC
2025-07-02

Henlius Receives New EMA GMP Certification, Accelerating European Market Entry of Two Biosimilar Candidates
2025-07-02

Henlius and HanchorBio Collaborate to Develop Novel SIRPα-Fc Fusion Protein, Expanding Tumor Immunotherapy Layout
2025-06-26

Henlius Hosts Investigator Meeting for Bridging Study of Serplulimab in Japan
2025-06-25

Henlius Doses First Patient in Japanese Bridging Study of Serplulimab for Extensive-Stage Small Cell Lung Cancer
2025-06-24

Serplulimab Approved in the UK and India for the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer
2025-06-20

Henlius Shines at 2025 BIO International Convention, Showcasing Its Innovative Achievements